{"product_id":"curosurf-80mg-ml-suspension-1-5ml","title":"Curosurf 80mg\/ml Suspension 1.5ml","description":"\u003ch3\u003eDescription\u003c\/h3\u003e\u003cp\u003eCurosurf is a natural pulmonary surfactant suspension used for intratracheal treatment or prevention of respiratory distress syndrome in premature newborns. It helps reduce alveolar surface tension and improve lung compliance and oxygenation.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eManufacturer Name: Chiesi\u003c\/li\u003e\n\u003cli\u003eDrug Class: Natural pulmonary surfactant\u003c\/li\u003e\n\u003cli\u003eDosage Form: Intratracheal Suspension\u003c\/li\u003e\n\u003cli\u003eStorage: Store refrigerated at 2–8°C. Protect from light and do not freeze. Gently warm to room temperature before use and shake gently; unused opened suspension should be discarded according to institutional policy.\u003c\/li\u003e\n\u003cli\u003ePack Size: Pack of 1\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eIngredients\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003ePoractant alfa, a natural porcine-derived pulmonary surfactant: 80 mg\/mL\u003c\/li\u003e\n\u003cli\u003ePhospholipid-based surfactant preparation containing natural pulmonary surfactant components\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eBenefits\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003ePrevention of respiratory distress syndrome in premature newborns at high risk due to surfactant deficiency\u003c\/li\u003e\n\u003cli\u003eTreatment of established neonatal respiratory distress syndrome\u003c\/li\u003e\n\u003cli\u003eSupports alveolar stability, lung compliance, and oxygen exchange in surfactant-deficient newborns\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eUsage \u0026amp; Safety\u003c\/h3\u003e\u003ch4\u003eFor Adult\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eNot indicated for routine adult use.\u003c\/li\u003e\n\u003cli\u003eMust be administered intratracheally by healthcare professionals experienced in neonatal respiratory care and mechanical ventilation.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eFor Children\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFor premature newborns with or at risk of respiratory distress syndrome.\u003c\/li\u003e\n\u003cli\u003eUsual initial dose: 200 mg\/kg intratracheally, equivalent to 2.5 mL\/kg.\u003c\/li\u003e\n\u003cli\u003eIf respiratory distress persists or worsens, additional doses of 100 mg\/kg, equivalent to 1.25 mL\/kg, may be given at approximately 12-hour intervals according to the neonatologist’s assessment.\u003c\/li\u003e\n\u003cli\u003eAdministration requires airway support, monitoring of oxygenation and ventilation, and readiness to manage rapid changes in lung compliance.\u003c\/li\u003e\n\u003cli\u003eNo routine dose is established for older children or adults.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eSide Effects\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eCommon or administration-related effects: bradycardia, oxygen desaturation, transient changes in blood pressure, airway obstruction, and reflux of product into the endotracheal tube.\u003c\/li\u003e\n\u003cli\u003eRespiratory effects may include worsening ventilation difficulty, pulmonary hemorrhage, pneumothorax, or need for adjustment of ventilator settings.\u003c\/li\u003e\n\u003cli\u003eSerious reactions may include severe hypoxia, persistent bradycardia, pulmonary hemorrhage, or hypersensitivity-type reactions.\u003c\/li\u003e\n\u003cli\u003eCareful monitoring is required during and after each dose.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eContraindications\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eKnown hypersensitivity to poractant alfa or any component of the product.\u003c\/li\u003e\n\u003cli\u003eDo not administer by intravenous, intramuscular, subcutaneous, oral, or other non-intratracheal routes.\u003c\/li\u003e\n\u003cli\u003eUse only under specialist neonatal supervision in a properly equipped clinical setting.\u003c\/li\u003e\n\u003cli\u003eTransient airway obstruction, bradycardia, oxygen desaturation, or reflux of the suspension may occur during administration; ventilation and airway management should be immediately available.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003ePrecautions \u0026amp; Warnings\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eNo clinically important systemic drug interactions are generally expected because the product is administered directly into the lungs.\u003c\/li\u003e\n\u003cli\u003eDo not mix with other medicines or diluents in the same vial, syringe, or airway circuit unless compatibility has been specifically established.\u003c\/li\u003e\n\u003cli\u003eOther respiratory treatments and ventilator settings may need adjustment because lung compliance and oxygenation can improve rapidly after dosing.\u003c\/li\u003e\n\u003cli\u003eConcurrent airway medications should be administered only according to neonatal intensive-care protocols.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003ePregnancy\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eThis product is intended for administration to newborns and is not used as a maternal treatment during pregnancy.\u003c\/li\u003e\n\u003cli\u003eMaternal pregnancy exposure information is not applicable to routine use.\u003c\/li\u003e\n\u003cli\u003eBreastfeeding considerations are not applicable when the product is administered intratracheally to a newborn.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Chiesi","offers":[{"title":"Default Title","offer_id":66743584751731,"sku":"309234","price":39361.0,"currency_code":"PKR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0675\/9910\/6163\/files\/Curosurf_1_5ml_Supension.png?v=1790705502","url":"https:\/\/alrehmanpharmacy.com\/products\/curosurf-80mg-ml-suspension-1-5ml","provider":"Al-Rehman Pharmacy \u0026 Cosmetics","version":"1.0","type":"link"}